- Home
- DMAC vs CZWI Comparison
DMAC vs CZWI Comparison
Compare DMAC & CZWI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- CZWI
- Stock Information
- Founded
- DMAC 2000
- CZWI 1938
- Country
- DMAC United States
- CZWI United States
- Employees
- DMAC N/A
- CZWI N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- CZWI Savings Institutions
- Sector
- DMAC Health Care
- CZWI Finance
- Exchange
- DMAC Nasdaq
- CZWI Nasdaq
- Market Cap
- DMAC 260.0M
- CZWI 154.7M
- IPO Year
- DMAC N/A
- CZWI N/A
- Fundamental
- Price
- DMAC $4.45
- CZWI $14.74
- Analyst Decision
- DMAC Strong Buy
- CZWI
- Analyst Count
- DMAC 4
- CZWI 0
- Target Price
- DMAC $10.75
- CZWI N/A
- AVG Volume (30 Days)
- DMAC 393.5K
- CZWI 47.0K
- Earning Date
- DMAC 08-06-2025
- CZWI 07-28-2025
- Dividend Yield
- DMAC N/A
- CZWI 2.43%
- EPS Growth
- DMAC N/A
- CZWI N/A
- EPS
- DMAC N/A
- CZWI 1.24
- Revenue
- DMAC N/A
- CZWI $58,007,000.00
- Revenue This Year
- DMAC N/A
- CZWI N/A
- Revenue Next Year
- DMAC N/A
- CZWI $13.16
- P/E Ratio
- DMAC N/A
- CZWI $11.95
- Revenue Growth
- DMAC N/A
- CZWI N/A
- 52 Week Low
- DMAC $3.19
- CZWI $11.74
- 52 Week High
- DMAC $6.82
- CZWI $17.04
- Technical
- Relative Strength Index (RSI)
- DMAC 53.15
- CZWI 51.35
- Support Level
- DMAC $4.81
- CZWI $14.73
- Resistance Level
- DMAC $5.60
- CZWI $15.03
- Average True Range (ATR)
- DMAC 0.49
- CZWI 0.30
- MACD
- DMAC 0.05
- CZWI -0.05
- Stochastic Oscillator
- DMAC 43.21
- CZWI 30.00
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About CZWI Citizens Community Bancorp Inc.
Citizens Community Bancorp Inc is a bank holding company that offers traditional community banking services to businesses, Agricultural operators, and consumers, including one-to-four-family residential mortgages. it also offers a variety of loan products including commercial real estate loans, commercial and industrial (C&I) loans, agricultural real estate loans, agricultural operating loans, residential mortgages, home equity lines-of-credit, and consumer loans and offers deposit products through its branches, including demand deposits, various savings and money-market accounts and certificates of deposit. The company's sources of funds are deposits; amortization, prepayments, and maturities of outstanding loans; other short- term investments; and funds provided from operations.